Non-GLP Toxicology & Screening – Preclinical Development Services
Fast, flexible non-GLP studies to de-risk your lead compound before committing to GLP testing
Why Non-GLP Screening Studies Matter
Readily available to guide you through the study design process and support you in accelerating your preclinical research
Before committing to a full GLP toxicology program, most sponsors need faster, more flexible studies to confirm dose range, tolerability, and translational relevance. Non-GLP screening studies let you make informed go/no-go decisions early, without the cost and lead time of a GLP-compliant program.
Our team designs non-GLP studies tailored to your molecule and development stage, applying the same scientific rigor that carries through into GLP testing when your program is ready for it.
When you’re ready to move forward, our GLP Safety Assessment team can take the same lead compound through IND-enabling testing.
Notre approche
Tailored Study Design From Discovery Through Screening
Our team applies a tailored approach to the pharmacology and toxicology aspects of your research, adjusting study design on a case-by-case basis. With a broad portfolio of methods and models, we help determine the transferability and reliability of your results, supporting the transition of your compounds from bench to clinic.
Our team can also support your clinical hypothesis using a pharmacometrics approach. Using tools such as population-based pharmacokinetic modeling (PopPK), we help you optimize your clinical setup for specific patient substrata.
Collaborez avec un expert pour faire progresser vos recherches thérapeutiques.
Collaborez avec notre équipe pour évaluer votre médicament et sa cible thérapeutique avec précision et expertise
Nos compétences
Non-GLP Pharmacology and Toxicology Capabilities
Our team is equipped to provide non-GLP preclinical studies in rodents, along with safety pharmacology studies across various in vitro model systems. An established third-party partner extends this support to non-rodent species when needed.
Our in vitro toxicology portfolio continues to expand, including new approach methodologies (NAMs) such as genetic toxicity, mutagenicity, carcinogenicity, liver toxicity, cardiotoxicity, and neurotoxicity screening.
In Vivo Pharmacology
- DMPK properties
- Therapeutic efficacy studies
- Pharmacokinetics
- MTD (Maximum Tolerated Dose) determination
- Dose-response relations
- Translational disease models
Non-GLP Toxicology
- Non-GLP single-dose toxicity (acute tolerability screening)
- Non-GLP repeated-dose toxicity (dose range-finding)
- Toxicokinetics
- Medical device biocompatibility screening
Ready for GLP-Compliant Studies?
Once your program is ready to move into IND-enabling testing, our team supports the transition into GLP-compliant toxicology, safety pharmacology, and immunotoxicology studies.
Explorer le pipeline de développement de médicaments
Accréditation AAALAC
InnoSer a obtenu l'accréditation AAALAC, ce qui témoigne de notre engagement en faveur d'une prise en charge et d'une utilisation responsables des animaux. AAALAC International est une organisation à but non lucratif qui promeut le traitement sans cruauté des animaux dans le domaine scientifique par le biais de programmes volontaires d'accréditation et d'évaluation. Les sites d'InnoSer aux Pays-Bas et en Belgique sont accrédités par l'AAALAC depuis 2016 et 2020, respectivement. Pour en savoir plus sur le programme d'accréditation de l'AAALAC, cliquez ici.
Bien-être animal
Les « 3R » ont une incidence sur tous les domaines, depuis les changements politiques et réglementaires jusqu’au développement et à l’adoption de nouvelles technologies et approches. C’est pourquoi InnoSer s’engage en permanence à suivre ces processus. Les mesures que nous mettons en œuvre optimisent notre capacité à remplacer, réduire et perfectionner l’utilisation des animaux et facilitent notre engagement envers ces principes dans le cadre de la recherche et du développement de médicaments.
info@innoserlaboratories.com
Liens rapides